The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study - PubMed
7 days ago
- #immunotherapy
- #hepatocellular carcinoma
- #machine learning
- Study focused on using advanced machine learning to predict outcomes for advanced hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab.
- Retrospective cohort study conducted across 24 centers in eight countries, involving 774 patients after exclusions.
- Seven supervised machine learning models combined with 13 feature selection techniques were trained on 44 baseline clinical variables.
- Ensemble models for overall survival (OS) and progression-free survival (PFS) outperformed traditional clinical benchmarks.
- Patients were stratified into low-risk and high-risk groups, with significant differences in median OS and PFS between groups.
- The study suggests that machine learning models can improve personalized treatment strategies for HCC patients.